Hangzhou Zhongmei Files Generic-Style Roflumilast Trial for China Seborrheic Dermatitis
The Phase 3 study copies Arcutis's approved Zoryve regimen almost exactly, testing whether a Chinese sponsor can replicate an 79.5%-versus-58.0% precedent rather than break new clinical ground.
Executive Summary
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. registered a new Phase 3 trial, NCT07683806, testing Roflumilast Foam 0.3% against vehicle in 309 seborrheic dermatitis patients in China, targeting a primary completion date of 2027-06-30.
- The trial's primary endpoint, IGA success at Week 8, is identical to the endpoint Arcutis Biotherapeutics' completed STRATUM trial met at 79.5% versus 58.0% for vehicle (P<0.0001), making this a same-drug replication study rather than a novel mechanism test.
- The trial is Not yet recruiting with a planned start of 2026-08-24, so no enrollment, safety, or efficacy data exist; the real information value sits more than a year out.
- PDE4 as a target shows a declining pace of new trial starts, with a recent-to-older trial ratio of 0.08, positioning this filing as an entry into a mechanism class that is consolidating around Arcutis's approved product rather than expanding.
- The catalyst is a low-risk, high-precedent regional filing whose main value to investors is confirming whether a validated Western mechanism can be replicated in a Chinese population, not whether the drug works.
The new trial
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. added NCT07683806 to the ClinicalTrials.gov registry on 2026-07-06, a Phase 3, randomized, vehicle-controlled study of Roflumilast Foam 0.3% in patients ages 9 and older with seborrheic dermatitis. The trial targets 309 anticipated participants in China, with a planned start date of 2026-08-24 and a primary completion date of 2027-06-30. The registry title states the purpose plainly: 'Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis' Press ReleasePress ReleaseJul 6, 2026.
The endpoint bar
The primary outcome measure is the percentage of participants achieving IGA success at Week 8, defined as an Investigator Global Assessment score of clear or almost clear plus a 2-point improvement from baseline. That is the exact endpoint definition Arcutis Biotherapeutics used in its completed Phase 3 STRATUM trial (NCT04973228), which met its primary endpoint with 79.5% IGA success on roflumilast versus 58.0% on vehicle at Week 8, a statistically significant margin (P<0.0001). Arcutis also reported a second completed Phase 2 trial (NCT04091646) with 73.1% IGA success versus 40.8% for vehicle, and long-term safety follow-up out to 52 weeks showing treatment-emergent adverse events in 32.5% of 400 patients and serious adverse events in 1.8%, none treatment-related.
What is not yet known
No results are posted for NCT07683806 on ClinicalTrials.gov, and the trial has not begun recruiting. The registered protocol does not disclose the randomization ratio between roflumilast and vehicle arms, nor any planned regulatory filing pathway for China. Protocol stability tracking shows zero change events since registration and a 'Stable' label, though the trial is too new for that metric to carry weight.
Sponsor and field context
Hangzhou Zhongmei Huadong Pharmaceutical has completed 7 of 7 prior trials with no terminations, a 100% completion rate, and currently runs 45 trials across its broader portfolio, with 23 recruiting and 11 not yet recruiting. Roflumilast itself already carries FDA approval as Zoryve foam and cream for Arcutis, plus multiple oral tablet ANDA approvals for COPD, giving the molecule a long regulatory track record outside China. The broader PDE4 inhibitor class shows declining new-trial formation, with a 0.08 ratio of recent to older trials in the target, suggesting sponsors are consolidating around validated uses like this one rather than opening new indications.
What this does not resolve
This is a registry addition, not a data event: the trial's information value will not materialize until patient enrollment completes and Week 8 IGA data are reported, expected around the 2027-06-30 primary completion date. Because the design vehicle-controls against the same endpoint Arcutis already validated, the more useful investor lens is operational, whether the sponsor enrolls on schedule and whether the China population replicates the US effect size, rather than whether the mechanism itself works.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.